Lucid Diagnostics (Lucid Diagnostics) 3-Year Dividend Growth Rate : 0.00% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Lucid Diagnostics 3-Year Dividend Growth Rate?

Lucid Diagnostics's Dividends per Share for the three months ended in Mar. 2024 was $0.00.

The historical rank and industry rank for Lucid Diagnostics's 3-Year Dividend Growth Rate or its related term are showing as below:

LUCD's 3-Year Dividend Growth Rate is not ranked ^*
in the Medical Devices & Instruments industry.
Industry Median: 11.9
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Lucid Diagnostics's Dividend Payout Ratio for the three months ended in Mar. 2024 was 0.00. As of today, Lucid Diagnostics's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Lucid Diagnostics's 3-Year Dividend Growth Rate

For the Medical Devices subindustry, Lucid Diagnostics's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lucid Diagnostics's 3-Year Dividend Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Lucid Diagnostics's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Lucid Diagnostics's 3-Year Dividend Growth Rate falls into.

Lucid Diagnostics 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Lucid Diagnostics (NAS:LUCD) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Lucid Diagnostics's Dividend Payout Ratio for the quarter that ended in Mar. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Mar. 2024 )	/	EPS without NRI (Q: Mar. 2024 )
	=	0	/	-0.403
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lucid Diagnostics 3-Year Dividend Growth Rate Related Terms>

Lucid Diagnostics (Lucid Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lucid Diagnostics Inc (NAS:LUCD) » Definitions » 3-Year Dividend Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

360 Madison Avenue, 25th Floor, New York, NY, USA, 10017

Website

https://www.luciddx.com

Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.

Executives

Stanley Lapidus	director	101 HARTWELL AVE., LEXINGTON MA 02421
Debra White	director	C/O PAVMED INC., ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Michael Adam Gordon	officer: General Counsel	ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Shaun O'neil	officer: Chief Operating Officer	ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Pavmed Inc.	10 percent owner	360 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10017
Lishan Aklog	director, officer: Chief Executive Officer	420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10171
Dennis M Mcgrath	officer: Chief Financial Officer	C/O PAVMED INC., ONE GRAND CENTRAL PLACE, STE. 4600, NEW YORK NY 10165
Ronald M Sparks	director	420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
James L Cox	director	420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
Aster Angagaw	director	150 PEABODY PLACE, MEMPHIS TN 38103
Jacque J Sokolov	director
David F Wurtman	officer: Chief Medical Officer	ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165